Skip to main content

Table 2 Multivariate Cox proportional hazards regression analysis of the development cohort

From: Nomograms for predicting survival in patients with metastatic gastric adenocarcinoma who undergo palliative gastrectomy

 

Postoperative Model

Preoperative Model

HR a

95% CI b

P

HR

95% CI

P

Age (“≤65”as reference)

  

0.004

  

0.000

 66–80

1.075

0.935–1.236

0.311

1.285

1.123–1.470

0.000

 >80

1.391

1.143–1.694

0.001

1.977

1.643–2.378

0.000

Sex (“Male” as reference)

 Female

0.961

0.843–1.095

0.548

0.990

0.869–1.129

0.885

Race (“White” as reference)

  

0.600

  

0.593

 Black

0.984

0.823–1.177

0.863

0.962

0.805–1.148

0.665

 Other

0.923

0.789–1.079

0.313

0.923

0.791–1.078

0.314

Tumor location (“Cardia” as reference)

  

0.008

  

0.020

 Non-cardia

0.816

0.684–0.974

0.024

0.935

0.785–1.113

0.449

 Overlapping lesion

1.054

0.829–1.340

0.669

1.241

0.977–1.577

0.077

 Stomach, NOSc

1.014

0.784–1.312

0.915

1.129

0.876–1.455

0.348

Tumor size (“≤30 mm” as reference)

  

0.033

  

0.041

 31-50 mm

0.985

0.802–1.209

0.882

1.120

0.914–1.373

0.273

  > 50 mm

0.833

0.684–1.014

0.069

0.938

0.773–1.138

0.515

Subtype (“Intestinal type” as reference)

  

0.536

  

0.267

 Diffuse type

0.861

0.664–1.117

0.260

0.925

0.717–1.193

0.547

 Adenocarcinoma, NOS

0.997

0.846–1.175

0.972

1.095

0.932–1.287

0.269

 Other adenocarcinoma

0.906

0.708–1.159

0.431

0.943

0.738–1.206

0.642

Grade (“Grade1/2” as reference)

 Grade3/4

1.334

1.155–1.540

0.000

1.269

1.100–1.463

0.001

T category-AJCCd 7th (“T1” as reference)

  

0.000

  

0.000

 T2

1.395

0.894–2.179

0.143

1.252

0.803–1.953

0.321

 T3

1.906

1.341–2.708

0.000

1.658

1.171–2.348

0.004

 T4a

2.284

1.594–3.273

0.000

1.971

1.382–2.811

0.000

 T4b

2.457

1.704–3.542

0.000

2.128

1.481–3.058

0.000

N category-AJCC 7th (“N0” as reference)

  

0.000

   

 N1

1.341

1.082–1.662

0.007

–

–

–

 N2

2.003

1.579–2.542

0.000

–

–

–

 N3

2.128

1.617–2.801

0.000

–

–

–

 N+

–

–

–

1.397

1.137–1.717

0.001

Metastatic site(s) (“Distant LN(s)e” as reference)

  

0.000

  

0.000

 Viscera

1.496

1.255–1.783

0.000

1.586

1.334–1.886

0.000

 Viscera plus distant LN(s)

1.810

1.389–2.359

0.000

1.782

1.372–2.314

0.000

 Distant metastasis, NOS

1.748

1.223–2.497

0.002

1.664

1.173–2.362

0.004

Gastrectomy (“Partial gastrectomy” as reference)

  

0.078

   

 Near-total or total gastrectomy

0.838

0.718–0.978

0.025

–

–

–

 Gastrectomy, NOS

0.930

0.801–1.080

0.343

–

–

–

No. of regional LN(s) examined (“≤10” as reference)

 > 10

0.684

0.591–0.792

0.000

–

–

–

Surgery to other site(s) or node(s) (“No” as reference

 Yes

1.008

0.877–1.159

0.913

–

–

–

Chemotherapy (“No/Unknown” as reference

 Yes

0.514

0.448–0.589

0.000

–

–

–

Radiotherapy (“No/Unknown” as reference

 Yes

0.778

0.647–0.936

0.008

–

–

–

  1. ahazard ratio; bconfidence interval; cnot otherwise specified; dAmerican Joint Committee on Cancer; elymph node(s)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us